InnocsAI Acquired by Liminatus Pharma | Healthcare M&A Deal

Liminatus Pharma has acquired InnocsAI, a medical devices business in Delaware, for $0.20. Liminatus Pharma acquisitions focus on healthcare M&A, and InnocsAI is positioned to support medical devices acquisition through technology and regulated product development. The InnocsAI acquisition expands Liminatus Pharma’s capabilities in DE acquisitions and merger acquisition activities within the medical devices sector. The announced merger acquisition is a strategic acquisition by Liminatus Pharma, a strategic buyer pursuing healthcare deals DE, with deal terms governed by a merger agreement dated May 17, 2026.